Sarah Blach

7.4k total citations · 1 hit paper
43 papers, 2.3k citations indexed

About

Sarah Blach is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Sarah Blach has authored 43 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hepatology, 35 papers in Epidemiology and 1 paper in Infectious Diseases. Recurrent topics in Sarah Blach's work include Hepatitis C virus research (40 papers), Liver Disease Diagnosis and Treatment (27 papers) and Hepatitis B Virus Studies (27 papers). Sarah Blach is often cited by papers focused on Hepatitis C virus research (40 papers), Liver Disease Diagnosis and Treatment (27 papers) and Hepatitis B Virus Studies (27 papers). Sarah Blach collaborates with scholars based in Switzerland, United States and United Kingdom. Sarah Blach's co-authors include Homie Razavi, Chris Estes, Kathryn Razavi‐Shearer, E. Gower, Devin Razavi‐Shearer, Ivane Gamkrelidze, Ellen Dugan, Antonio Craxı̀, Loreta A. Kondili and Stefan Zeuzem and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Journal of Hepatology.

In The Last Decade

Sarah Blach

42 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global epidemiology and genotype distribution of the hepatitis C virus infection

2014 1.4k citations E. Gower, Chris Estes et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah Blach Switzerland	15	2.1k	2.0k	338	92	61	43	2.3k
Chris Estes United States	14	2.4k 1.2×	2.3k 1.2×	352 1.0×	101 1.1×	76 1.2×	25	2.7k
E. Gower Switzerland	5	1.8k 0.9×	1.7k 0.9×	444 1.3×	63 0.7×	69 1.1×	5	2.0k
Wendy Cheng Australia	23	1.1k 0.5×	1.0k 0.5×	253 0.7×	69 0.8×	104 1.7×	67	1.6k
Wolf Peter Hofmann Germany	24	1.8k 0.9×	1.7k 0.9×	268 0.8×	107 1.2×	167 2.7×	72	2.3k
Mark Danta Australia	20	1.3k 0.6×	1.2k 0.6×	460 1.4×	106 1.2×	125 2.0×	66	1.8k
Kathryn Razavi‐Shearer United States	7	1.5k 0.7×	1.4k 0.7×	207 0.6×	72 0.8×	63 1.0×	14	1.7k
Sabela Lens Spain	26	2.4k 1.1×	2.1k 1.1×	237 0.7×	155 1.7×	133 2.2×	119	2.7k
Reem Ghalib United States	18	2.7k 1.3×	2.3k 1.2×	547 1.6×	251 2.7×	125 2.0×	47	3.1k
Mariantonietta Pisaturo Italy	26	1.3k 0.6×	1.4k 0.7×	257 0.8×	72 0.8×	137 2.2×	102	1.8k
Maria Beumont United States	22	1.1k 0.5×	1.2k 0.6×	775 2.3×	124 1.3×	73 1.2×	55	1.8k

Countries citing papers authored by Sarah Blach

Since Specialization

Citations

This map shows the geographic impact of Sarah Blach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Blach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Blach more than expected).

Fields of papers citing papers by Sarah Blach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Blach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Blach. The network helps show where Sarah Blach may publish in the future.

Co-authorship network of co-authors of Sarah Blach

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Blach. A scholar is included among the top collaborators of Sarah Blach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Blach. Sarah Blach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Razavi‐Shearer, Devin, Ivane Gamkrelidze, Calvin Q. Pan, et al.. (2023). The impact of immigration on hepatitis B burden in the United States: a modelling study. The Lancet Regional Health - Americas. 22. 100516–100516. 14 indexed citations

Ezzat, Sameera, Ivane Gamkrelidze, Asmaa Gomaa, et al.. (2023). Impacts of the Egyptian national screening and treatment programme for viral hepatitis C: A cost‐effectiveness model. Liver International. 43(7). 1417–1426. 6 indexed citations

Negro, Francesco, Beat Müllhaupt, David Semela, et al.. (2023). The current and future burden of hepatitis B in Switzerland: a modelling study. Swiss Medical Weekly. 153(6). 40086–40086. 4 indexed citations

Schorr, Olivier, et al.. (2022). Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic. PLoS ONE. 17(8). e0272518–e0272518. 1 indexed citations

Blach, Sarah, Kimberly Brown, Robert S. Brown, et al.. (2022). Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress. Journal of Infection and Public Health. 16(1). 64–70. 7 indexed citations

Vince, Adriana, Ellen Dugan, Tatjana Nemeth Blažić, et al.. (2020). Strategies to eliminate hepatitis C in Croatia, a modelling study. University of Zagreb University Computing Centre (SRCE). 142(9-10). 2 indexed citations

Kondili, Loreta A., Ivane Gamkrelidze, Sarah Blach, et al.. (2020). Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver International. 40(7). 1545–1555. 31 indexed citations

Blach, Sarah, Loreta A. Kondili, Alessio Aghemo, et al.. (2020). Impact of COVID-19 on global HCV elimination efforts. Journal of Hepatology. 74(1). 31–36. 184 indexed citations

Lee, Kuan Ken, Dominik Stelzle, Rong Bing, et al.. (2019). Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. The Lancet. Gastroenterology & hepatology. 4(10). 794–804. 68 indexed citations

10.

Scott, Sarah Robbins, Homie Razavi, Pietro Vernazza, et al.. (2019). Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. Swiss Medical Weekly. 149(304). w14694–w14694. 5 indexed citations

11.

Schaefer, Benedikt, André Viveiros, Ramona Al‐Zoairy, et al.. (2018). Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030. PLoS ONE. 13(7). e0200750–e0200750. 4 indexed citations

12.

Grebely, Jason, Sarah Larney, Amy Peacock, et al.. (2018). Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 114(1). 150–166. 174 indexed citations

13.

Müllhaupt, Beat, Philip Bruggmann, Florian Bihl, et al.. (2018). Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. PLoS ONE. 13(12). e0209374–e0209374. 9 indexed citations

14.

Gountas, Ilias, Vana Sypsa, Sarah Blach, Homie Razavi, & Angelos Hatzakis. (2018). HCV elimination among people who inject drugs. Modelling pre- and post–WHO elimination era. PLoS ONE. 13(8). e0202109–e0202109. 20 indexed citations

15.

Gountas, Ilias, Ivane Gamkrelidze, Sarah Blach, et al.. (2017). HCV elimination among people who inject drugs. What would happen after the WHO HCV elimination target is achieved?. Journal of Hepatology. 66(1). S405–S406. 1 indexed citations

16.

Bruggmann, Philip, Sarah Blach, Pierre Deltenre, et al.. (2017). Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Medical Weekly. 147(4546). w14543–w14543. 13 indexed citations

17.

Müllhaupt, Beat, Philip Bruggmann, Florian Bihl, et al.. (2015). Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS ONE. 10(6). e0125214–e0125214. 22 indexed citations

18.

Gower, E., Chris Estes, Sarah Blach, Kathryn Razavi‐Shearer, & Homie Razavi. (2014). Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology. 61(1). S45–S57. 1402 indexed citations breakdown →

19.

Cramp, Matthew, William Rosenberg, Stephen Ryder, Sarah Blach, & Julie Parkes. (2014). Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterology. 14(1). 137–137. 26 indexed citations

20.

Descamps, V., et al.. (2001). Chronic radiodermatitis after cardiac catheterization. Catheterization and Cardiovascular Interventions. 52(2). 235–236. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact